🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT06491095
Starting soon Not applicable

Effect of Flax in Yogurt on Blood Cyanide Levels

NCT06491095 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2025-01-16
Last updated
2024-12-02

Condition(s) studied

Healthy

Investigational drug(s) / intervention(s)

0 g Flax40 g whole ground flaxseed40 g roasted then ground whole flaxseed40 g of whole intact flaxseeds28 g flax hulls

0 g Flax: 175 g yogurt with no flax product

40 g whole ground flaxseed: 175 g yogurt with 40 g whole ground flaxseed

40 g roasted then ground whole flaxseed: 175 g yogurt with 40 g roasted then ground whole flaxseed

40 g of whole intact flaxseeds: 175 g yogurt with 40 g of whole intact flaxseeds

28 g flax hulls: 175 g yogurt with 28 g flax hulls

Study summary

A randomized, controlled, cross-over post-prandial trial in healthy human volunteers will be conducted at the IH Asper Institute to determine the effect whole ground flaxseed, roasted then ground whole flaxseed, whole intact flaxseed and flaxseed hulls mixed into yogurt on blood cyanide levels.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Generally healthy adult, 18 years or older; 2. Willing to provide informed consent; 3. Willing/able to comply with the requirements of the study. Exclusion Criteria: 1. Pregnant or lactating; 2. Medical history of disease that is currently under treatment; 3. Active treatment for any type of cancer within 1 year prior to study start; 4. Presence of a gastrointestinal disorder, daily use of any stomach acid-lowering medications or laxatives (including fibre supplements) within the past month or antibiotic use within the past 6 weeks; 5. Plasma concentration of vitamin B12 \< 148 pmol/L; 6. Complete blood count outside normal range; 7. Medical history of liver disease or liver dysfunction (defined as plasma AST or ALT ≥3 times the upper limit of normal (ULN)); 8. Fasting blood glucose ≥6.1 mmol/L and/or HbA1c ≥6.0%; 9. Fasting plasma total cholesterol \>7.8 mmol/L; 10. Fasting plasma HDL \<0.9 mmol/L; 11. Fasting plasma LDL \>5.0 mmol/L; 12. Fasting plasma triglycerides \>2.3 mmol/L; 13. Systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg; 14. Major surgery within the last 3 months; 15. Smoking, use of tobacco, vape or cannabis (within the last week); 16. Allergies to flaxseed or yogurt; 17. Aversion or unwillingness to eat study foods; 18. Participation in another clinical trial, current or in the past 4 weeks

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
I. H. Asper Clinical Research Institute Winnipeg Manitoba

More St. Boniface Hospital trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06491095 on ClinicalTrials.gov ↗ ← All trials in Canada